97 related articles for article (PubMed ID: 11980132)
1. [Pharmacokinetic of prednisolone in patients with rheumatoid arthritis].
Chekalin AF; Rossokhin VF; Shishkanov SF; Nesterov SL
Ter Arkh; 2002; 74(3):79-80. PubMed ID: 11980132
[TBL] [Abstract][Full Text] [Related]
2. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
[TBL] [Abstract][Full Text] [Related]
3. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2004 Apr; 31(4):645-8. PubMed ID: 15088287
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
Petersen KB; Jusko WJ; Rasmussen M; Schmiegelow K
Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic comparison of two oral liquid glucocorticoid formulations.
Kamada AK; Wiener MB; LaVallee NM; Scott MB; Selner JC; Szefler SJ
Pharmacotherapy; 1997; 17(2):353-6. PubMed ID: 9085328
[TBL] [Abstract][Full Text] [Related]
7. Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density.
Tengstrand B; Larsson E; Klareskog L; Hafström I
Scand J Rheumatol; 2007; 36(5):351-8. PubMed ID: 17963164
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis.
Gerlag DM; Haringman JJ; Smeets TJ; Zwinderman AH; Kraan MC; Laud PJ; Morgan S; Nash AF; Tak PP
Arthritis Rheum; 2004 Dec; 50(12):3783-91. PubMed ID: 15593225
[TBL] [Abstract][Full Text] [Related]
9. Detection of prednisolone in vitreous following systemic administration.
Flaxel CJ; Wheeler MJ; Mulholland B; Gregor ZJ
Eye (Lond); 1998; 12 ( Pt 6)():1013-4. PubMed ID: 10326006
[No Abstract] [Full Text] [Related]
10. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
[TBL] [Abstract][Full Text] [Related]
11. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis.
Kirwan JR; Hickey SH; Hällgren R; Mielants H; Björck E; Persson T; Wollheim FA
Arthritis Rheum; 2006 May; 54(5):1415-21. PubMed ID: 16645969
[TBL] [Abstract][Full Text] [Related]
12. Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data.
Bannwarth B; Schaeverbeke T; Péhourcq F; Vernhes JP; D'Yvoire MB; Dehais J
Rev Rhum Engl Ed; 1997 May; 64(5):301-4. PubMed ID: 9190003
[TBL] [Abstract][Full Text] [Related]
13. Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study.
Needs CJ; Smith M; Boutagy J; Donovan S; Cosh D; McCredie M; Brooks PM
J Rheumatol; 1988 Feb; 15(2):224-8. PubMed ID: 3361533
[TBL] [Abstract][Full Text] [Related]
14. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study.
Hafström I; Rohani M; Deneberg S; Wörnert M; Jogestrand T; Frostegård J
J Rheumatol; 2007 Sep; 34(9):1810-6. PubMed ID: 17696277
[TBL] [Abstract][Full Text] [Related]
15. Are there patients with inflammatory disease who do not respond to prednisone?
Sen D; Rajbhandary R; Carlino A; Anderson RJ; Schur PH; Panush RS
J Rheumatol; 2010 Aug; 37(8):1559-61. PubMed ID: 20675852
[No Abstract] [Full Text] [Related]
16. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
[TBL] [Abstract][Full Text] [Related]
17. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
Straub RH; Pongratz G; Schölmerich J; Kees F; Schaible TF; Antoni C; Kalden JR; Lorenz HM
Arthritis Rheum; 2003 Jun; 48(6):1504-12. PubMed ID: 12794817
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of prednisolone and its local anti-inflammatory steroid-21-oate ester derivatives. In vitro and in vivo comparative study.
al-Habet SM; Taraporewala IB; Lee HJ
Drug Metab Dispos; 1990; 18(1):55-60. PubMed ID: 1970778
[TBL] [Abstract][Full Text] [Related]
19. [Effect of small-dose glucocorticoids on the course of early rheumatic arthritis].
Suponitskaia EV; Smirnov AV; Aleksandrova EN; Novikov AA; Nasonov EL
Klin Med (Mosk); 2004; 82(9):39-42. PubMed ID: 15540421
[TBL] [Abstract][Full Text] [Related]
20. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
Stamp LK; O'Donnell JL; Chapman PT; Zhang M; Frampton C; James J; Barclay ML
Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
